Transcriptome profiles acquired during cell expansion and licensing validate mesenchymal stromal cell lineage genes.

ABSTRACT:

Background

Mesenchymal stromal cells (MSCs) are rapidly advancing as commercial therapeutics. However, there are still no adequate tools to validate the identity of MSCs and support standardization of MSC-based products. Currently accepted metrics include cell surface marker profiling and tri-lineage differentiation assays, neither of which is definitive. Transcript profiling represents a cost- and time-effective approach amenable to MSC manufacturing processes. Two independent labs recently reported non-overlapping MSC-specific transcriptomic signatures of 489 and 16 genes.

Methods

Here, we interrogated our repository of transcriptome data to determine whether routine culture manipulations including cell expansion and immune activation affect expression of the reported MSC

SUBMITTER: Wiese DM 

PROVIDER: S-EPMC7427746 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature